https://www.selleckchem.com/pr....oducts/stat3-in-1.ht
The aim of the study was to update our experience treating patients with glottic carcinoma in situ (CIS) with curative radiotherapy (RT). Fifty patients received continuous-course RT using once-daily fractionation. Twenty-eight (56%) had recurrent or persistent CIS after resection. Median total dose was 63.0 Gy; median dose per fraction was 2.25 Gy. Median follow-up was 9.6 years for all patients and 8.4 years for survivors. After RT, 5 patients (10%) recurred locally; salvage surgery was performed in 4 (1 refused). Five-year outcome
Like
Comment
Share
